NEWSWIRETODAY Press Release& Newswire Distribution | HOME
PRTODAY / NewswireToday press release distribution service network
More news: Research
Agency / Source: Bruker Corporation

Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Bruker’s Molecular Phenomics Research Tools Enable New Insights into ‘Long COVID’ and Post-Acute Metabolic Abnormalities - Australian National Phenome Centre Integrates Quantitative NMR and MS Assay Platform for Risk Assessment and Longitudinal Monitoring of Post-Acute COVID-19 Syndrome (PACS) - / /
Bruker’s Molecular Phenomics Research Tools Enable New Insights into ‘Long COVID’ and Post-Acute Metabolic Abnormalities


NewswireTODAY - /newswire/ - Perth, Western Australia, Australia, 2021/05/20 - Australian National Phenome Centre Integrates Quantitative NMR and MS Assay Platform for Risk Assessment and Longitudinal Monitoring of Post-Acute COVID-19 Syndrome (PACS) - / / NASDAQ: BRKR

Your Banner Ad Here instead - Showing along with ALL Articles covering Research Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


A clinical research collaboration on COVID-19 pheno-conversion and subsequent pheno-reversion has discovered transient and persistent systemic changes of the molecular signatures in patient blood samples three months after the acute COVID-19 disease phase. These biochemical abnormalities, identified by a quantitative, label-free assay platform integrating nuclear magnetic resonance (NMR) spectroscopy and mass spectrometry (MS), relate to ongoing ‘long COVID’ symptoms, which persist post-acute infection and can affect more than half of the recovered COVID patients - even six months after infection.

A series of seminal papers on the molecular phenome of acute disease and post-acute COVID syndrome in patient plasma has been announced ( and published (1-5) by the Australian National Phenome Centre (ANPC) at Murdoch University, in collaboration with other academic medical centers, and with Bruker Corporation as a key technology partner.

The integrated, quantitative NMR and MS assay platform, which is for research use only, has revealed metabolic abnormalities, interactions of metabolic markers with cytokines, as well as interactions of lipoproteins with inflammation markers, caused by acute COVID-19. It enabled the creation of a multi-assay panel of pheno-conversion markers that change significantly during disease progression. This molecular phenomics panel can now also provide a measure of a patient’s partial recovery, or of emerging chronic PACS risks, e.g., for new-onset diabetes or for new-onset atherosclerosis, and for other persistent or reoccurring symptoms, including chronic fatigue, ‘brain fog’ and numerous other reported long COVID symptoms.

Post-acute follow up studies on non-hospitalized and mildly affected COVID-19 patients revealed that the majority of these patients is not back to normal health or normal biochemistry three months on and suffers from PACS, also referred to as ‘Long COVID’, characterized by persistent symptoms and health dysfunction after the acute infection. More than 57% of these patients show one or more symptoms up to six months following the acute phase, and many of them have metabolic abnormalities as revealed by the NMR and MS based pheno-reversion panel.

Professor Jeremy Nicholson, Pro Vice Chancellor for the Health Futures Institute at Murdoch University and Director of the ANPC explained: “Advanced NMR- and MS-screening of blood plasma provides complementary insights into the complex COVID-19 systemic pattern. There were multiple but variable biochemical abnormalities in the follow up patients with a variety of partial recovery phenotypes. We noted that most of the follow up COVID-19 patients had metabolic abnormalities irrespective of whether they were still symptomatic, but symptomatic patients were statistically more likely to have biochemical abnormalities.”
He continued: “This is an immensely dangerous disease that is not only costing lives today, but as we’re discovering now, may have serious health consequences for some patients long into the future, even in relatively mild original cases.”

The majority of patients at three months post-acute phase have a variety of blood metabolic abnormalities that differ between symptomatic and asymptomatic at six months. The researchers found that plasma lipoproteins in the blood of COVID-19 patients changed during infection and came closer to patterns typically found in patients with diabetes and atherosclerosis. Some abnormalities were reduced in the follow up patients and were reversible, whereas markers related to liver, energy metabolism and neuro-pathologies were often not completely reversed.

The latest research is consistent with earlier findings from the ANPC that showed COVID-19 is a systemic disease with multi-organ effects. The concept of pheno-conversion, as expressed in the lipoprotein and metabolic profile of blood plasma, establishes molecular phenotype biomarkers that can be analyzed for disease progression, severity and treatment. This underlines the importance of longitudinal studies on recovered patients for PACS effects and long-term health risks.

ANPC also devised a novel relaxation and diffusion edited NMR method that refined selectivity and led to the discovery of novel phospholipid signals from supramolecular clusters (3). “This is the first example of motional editing of complex blood plasma spectra to enhance the selectivity of a diagnostic procedure and opens the door to other NMR approaches to classification based on the dynamics of molecules, as well as on concentrations,” added Professor Nicholson.

Dr. Manfred Spraul, the CTO at Bruker BioSpin’s Applied, Industrial and Clinical Division, commented: “These findings underline the potential of our integrated NMR and MS assay platform for risk screening for PACS. Our research methods are robust and transferable for personalized molecular phenome signatures, providing a gateway to better understanding the long-term effects of COVID-19. These molecular phenotype insights are eventually expected to support better post-acute COVID-19 patient management for faster recovery, and a reduction in healthcare costs.”

The COVID-19 pheno-conversion and pheno-reversion signatures are detected by combined NMR and MS assays, providing complementary insights into potential biomarkers for cardiology, metabolism, diabetes, kidney disease, liver function, neurological effects, and inflammation.

Bruker has begun validation of this integrated NMR/MS clinical research assay set in Europe, with the goal of developing PACS personalized risk screening and longitudinal patient monitoring diagnostic methods.

Dr. Óscar Millet, Principal Investigator at CIC bioGUNE in Bilbao, Spain, commented: “As one of the key clinical research labs for precision medicine in Europe, we see huge potential for the PACS research enabled by high performance NMR and MS technology. We are an active member of the International COVID-19 research network, which is led by the ANPC. The harmonized research approach, which is based on standardized operating procedures developed by ANPC and Bruker, has allowed us to study PACS on Spanish patient cohorts and cross-validate our data with those of the ANPC at both the analytical and biological level.”

The studies were conducted using Avance™ IVDr NMR 600 MHz spectrometers integrated in the ANPC class II biosecurity laboratory, together with Bruker and CIC bioGUNE in-vitro diagnostics NMR research (IVDr) technology methods. The ANPC has also equipped its molecular phenomics lab with state-of-the-art mass spectrometers, including Bruker impact II and timsTOF™ Pro QTOF-MS, and a solariX™ MRMS system.

About the Australian National Phenome Centre

The Australian National Phenome Centre (ANPC) (, at Murdoch University, will help transform how long and how well people live, not just in Australia, but around the world. The work of the ANPC supports almost every area of bioscience. It reaches across traditional research silos and fosters a new, more collaborative approach to science. Long-term, the ANPC hopes to build ‘global atlases’ of human disease, providing insights into future health risks which everyone on the planet can benefit from. The only facility of its kind in the southern hemisphere, the ANPC brings together other western Australian universities and leading health and medical research institutes. It is linked to the International Phenome Centre Network and also has wide research activities in agriculture and environmental science. The ANPC helps to position Perth and Western Australia as a major leader in precision medicine, and enables quantum leaps in predicting, diagnosing and managing human disease. It is part of the Health Futures Institute at Murdoch University.

About CIC bioGUNE

The bioGUNE Research Center (, based in the Bizkaia Science and Technology Park, is a biomedical research organization that develops cutting-edge research on the interface between structural, molecular and cellular biology, with special attention to the study of the molecular bases of disease, to be used in the development of new diagnostic methods and advanced therapies. CIC bioGUNE is recognized as a “Severo Ochoa Center of Excellence”, the highest recognition of centers of excellence in Spain. CIC bioGUNE is equipped with state-of-the art facilities for metabolomic analyses, including two IVDr NMR spectrometers and an Impact II mass spectrometer. CIC bioGUNE is leading an ambitious project in precision medicine (Akribea) to develop improved personalized diagnostic methods. Akribea project will target a segment of the population in the Basque Country (10.000 subjects) during several years to create a sample/data repository and the accessory biobanking and data mining capacities.

About Bruker Corporation

Bruker ( is enabling scientists to make breakthrough discoveries and develop new applications that improve the quality of human life. Bruker’s high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity and customer success in life science molecular and cell biology research, in applied and pharma applications, in microscopy and nanoanalysis, as well as in industrial applications. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics.

Investor Contact: Miroslava Minkova - Senior Director, Investor Relations & Corporate Development
T: +1 978-663-3660 x1479 - E: Investor.Relations[.]

Your Banner Ad Here instead - Showing along with ALL Articles covering Research Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


Agency / Source: Bruker Corporation


Availability: All Regions (Including Int'l)


Traffic Booster: [/] Quick NewswireToday Visibility Checker


Distribution / Indexing: [+]  / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

# # #
  Your Banner Ad showing on ALL
Research articles,
CATCH Visitors via Your Competitors Announcements!

Bruker’s Molecular Phenomics Research Tools Enable New Insights into ‘Long COVID’ and Post-Acute Metabolic Abnormalities

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name NewswireToday and LINK as the source.
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
ANPC IVD-R 600 MHz NMR | Bruker Corporation
Contact: Thorsten Thiel, Ph.D. - 
+49(721) 5161 6500 thorsten.thiel[.]
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Bruker Corporation securities in any jurisdiction including any other companies listed or named in this release.

Research via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Read Latest Articles From Bruker Corporation / Company Profile

Read Research Most Recent Related Newswires:

Siemens and Centrale Nantes to Continue Cutting-edge Simulation Research
Thales and Marvel Fusion Cooperate with ELI-NP
Bruker Completes the Acquisition of Neurescence, Inc.
BASF Formaldpure™ Catalyst Receives 2022 Edison Patent Award
BASF Presents New Research Findings and Novelties in Applied Methods Technologies At IFSCC Congress
Benchtop FT-NMR Applied to SARS-CoV-2 and ‘Long COVID’ Research Lowers the Barrier to Clinical Translation
The Outbreak of COVID-19 Unlocked the Demand for Antimicrobial Technologies Says Frost & Sullivan
World Congress DSA 2023 - The Frontiers in Intelligent Data and Signal Analysis, New York, USA, July
Optina Diagnostics Earns Frost & Sullivan’s 2022 North American Technology Innovation Leadership Award for Leveraging Innovative Eye Imagery
ZAGENO Applauded by Frost & Sullivan for Simplifying the Supply Chain for Life Science Research with its e-Commerce Platform
Bruker Launches NMR-based Molecular Phenomics Clinical Research Tool for ‘Long COVID’ Multi-Organ Risk Assessment
Otto Schott Research Award Recognizes Achievements in Glass Science
Swave, A New Imec and VUB, Spin-off, Raises €7M to Deliver Truly Realistic AR/VR Experiences to Applications Like The Metaverse
Frost & Sullivan Awards EBSCO Information Services for Delivering Innovative Solutions to Access Medical Research Information for Healthcare Providers
Elanco and Royal DSM Announce Strategic Alliance in U.S. for Bovaer® A Revolutionary, Methane-Reducing Feed Additive for Cattle

Boost Your Social Network
& Crowdfunding Campaigns

NewswireToday Celebrates 10 Years in Business


Visit Omnitronics, Inc.

Visit  Power 1 Energy Company

  ©2005-2023 NewswireToday — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution newswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
PRTODAY & NewswireTODAY are proudly NOT affiliated with USA TODAY (